Trial Profile
A Phase I/Ib, Open Label Study of LSZ102 Single Agent and LSZ102 in Combination With Either LEE011 (LSZ102 + LEE011) or BYL719 (LSZ102 + BYL719) in Patients With Advanced or Metastatic ER+ Breast Cancer Who Have Progressed After Endocrine Therapy
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 12 Oct 2021
Price :
$35
*
At a glance
- Drugs Alpelisib (Primary) ; LSZ 102 (Primary) ; Ribociclib (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions; First in man
- Sponsors Novartis Pharmaceuticals
- 04 Oct 2021 Status changed from active, no longer recruiting to discontinued as per sponsors decision
- 03 Sep 2021 Planned End Date changed from 30 Jul 2021 to 15 Oct 2021.
- 03 Sep 2021 Planned primary completion date changed from 30 Jul 2021 to 15 Oct 2021.